2025Q4
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| Keyoung Hansoo Michael | — | 1,133,596 | Sep 29, 2020 |
| Orbimed Advisors Llc | 10% Owner | 846,574 | Sep 29, 2020 |
| OrbiMed Capital GP VI LLC | 10% Owner | 846,574 | Sep 29, 2020 |
| Wilson Robert N | Director | 422,029 | Jul 18, 2025 |
| Flynn James E | 10% Owner | 291,467 | Oct 1, 2020 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Oct 13, 2025 | Oct 14, 2025 | Glicklich Alan | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Sep 18, 2025 | Sep 22, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 60.0 | +2,500 | 0.24% | ✗ | $7.7K |
| Sep 15, 2025 | Sep 17, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 60.0 | +3,400 | 0.32% | ✗ | $9.1K |
| Sep 12, 2025 | Sep 15, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 61.3 | +5,000 | 0.47% | ✗ | $15.6K |
| Sep 9, 2025 | Sep 11, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 60.0 | +2,343 | 0.22% | ✗ | $7.4K |
| Aug 28, 2025 | Sep 2, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 68.8 | +10,000 | 0.96% | ✗ | $28.5K |
| Aug 21, 2025 | Aug 25, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 60.0 | +3,508 | 0.34% | ✗ | $9.8K |
| Aug 19, 2025 | Aug 21, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 60.0 | +3,000 | 0.35% | ✗ | $8.2K |
| Aug 19, 2025 | Aug 21, 2025 | Hebbar Sudarshan | Chief Medical Officer | Buy | 91.3 | +9,563 | 18.40% | ✗ | $27K |
| Aug 15, 2025 | Aug 19, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 68.8 | +5,076 | 0.50% | ✗ | $14.7K |
| Aug 14, 2025 | Aug 18, 2025 | Hebbar Sudarshan | Chief Medical Officer | Buy | 91.3 | +5,976 | 12.99% | ✗ | $16.4K |
| Jul 25, 2025 | Jul 29, 2025 | Stauderman Kenneth A. | Chief Scientific Officer | Buy | 52.5 | - | 0.00% | ✗ | $310 |
| Jul 22, 2025 | Jul 23, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 55.0 | +1,500 | 0.15% | ✗ | $5.7K |
| Jul 21, 2025 | Jul 22, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 55.0 | +1,500 | 0.15% | ✗ | $5.1K |
| Jul 21, 2025 | Jul 21, 2025 | Leheny A. Rachel | CEO | Buy | 55.0 | +1,000 | 0.11% | ✗ | $3.4K |
| Jul 18, 2025 | Jul 18, 2025 | WILSON ROBERT N | Director | Buy | 78.8 | +4,500 | 1.08% | ✗ | $12.9K |
| Jul 18, 2025 | Jul 18, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 55.0 | +2,000 | 0.20% | ✗ | $5.8K |
| Jul 14, 2025 | Jul 16, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 68.8 | +6,500 | 0.65% | ✗ | $15.8K |
| Jul 14, 2025 | Jul 15, 2025 | Leheny A. Rachel | CEO | Buy | 60.0 | +2,500 | 0.29% | ✗ | $6.2K |
| Jul 9, 2025 | Jul 10, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 67.5 | +5,000 | 0.50% | ✗ | $8K |
| Jul 1, 2025 | Jul 2, 2025 | Stauderman Kenneth A. | Chief Scientific Officer | Buy | 85.0 | +1,000 | 8.37% | ✗ | $1.9K |
| Jun 26, 2025 | Jun 27, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 60.0 | +4,500 | 0.45% | ✗ | $6.5K |
| Jun 24, 2025 | Jun 26, 2025 | Hebbar Sudarshan | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 26, 2025 | Jun 26, 2025 | Bardin Stephen | CFO | Buy | 82.5 | +2,000 | 4.88% | ✗ | $3K |
| Jun 24, 2025 | Jun 26, 2025 | Stauderman Kenneth A. | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 24, 2025 | Jun 26, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 24, 2025 | Jun 26, 2025 | Dunn Michael J. | COO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 24, 2025 | Jun 26, 2025 | Leheny A. Rachel | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 24, 2025 | Jun 26, 2025 | Guerard Frederic | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 24, 2025 | Jun 26, 2025 | Glicklich Alan | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 24, 2025 | Jun 26, 2025 | Shaw Allan | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 24, 2025 | Jun 26, 2025 | WILSON ROBERT N | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 24, 2025 | Jun 26, 2025 | MIDDLETON FRED A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 11, 2025 | Jun 13, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 67.5 | +5,000 | 0.51% | ✗ | $9.3K |
| Jun 5, 2025 | Jun 9, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 78.8 | +10,100 | 1.03% | ✗ | $17.5K |
| May 30, 2025 | Jun 3, 2025 | Bardin Stephen | CFO | Buy | 82.5 | +1,000 | 2.50% | ✗ | $1.7K |
| Apr 23, 2025 | Apr 25, 2025 | Bardin Stephen | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 23, 2025 | Apr 25, 2025 | Stauderman Kenneth A. | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 23, 2025 | Apr 25, 2025 | Dunn Michael J. | COO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 23, 2025 | Apr 25, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 23, 2025 | Apr 25, 2025 | Hebbar Sudarshan | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 23, 2025 | Apr 25, 2025 | Leheny A. Rachel | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 15, 2025 | Jan 16, 2025 | Glicklich Alan | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 16, 2025 | Glicklich Alan | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Dec 6, 2024 | Dec 6, 2024 | MIDDLETON FRED A | Director | Buy | 56.3 | +4,800 | 0.20% | ✗ | $12.7K |
| Nov 15, 2024 | Bardin Stephen | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| May 17, 2023 | Nov 6, 2024 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 90.0 | +3,000 | 100.00% | ✗ | $8K |
| Nov 1, 2024 | Nov 5, 2024 | Sanderling Venture Partners VI Co Investment Fund LP | 10% Owner | Buy | 90.0 | +87,744 | 3.78% | ✗ | $329K |
| Nov 1, 2024 | Nov 5, 2024 | MIDDLETON FRED A | Director | Buy | 90.0 | +107,744 | 4.61% | ✗ | $404K |
| Nov 1, 2024 | Nov 1, 2024 | Leheny A. Rachel | CEO | Buy | 82.5 | +20,000 | 2.35% | ✗ | $75K |
| Nov 1, 2024 | Nov 1, 2024 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 90.0 | +53,333 | 5.79% | ✗ | $200K |
| Nov 1, 2024 | Nov 1, 2024 | WILSON ROBERT N | Director | Buy | 95.0 | +53,333 | 14.64% | ✗ | $200K |
| Sep 9, 2024 | Sep 11, 2024 | Dunn Michael J. | COO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 27, 2024 | Aug 28, 2024 | Guerard Frederic | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 27, 2024 | Aug 28, 2024 | BJERKHOLT ERIC | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 27, 2024 | Aug 28, 2024 | Shaw Allan | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 27, 2024 | Aug 28, 2024 | MIDDLETON FRED A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 27, 2024 | Aug 28, 2024 | WILSON ROBERT N | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 27, 2024 | Aug 28, 2024 | Dunn Michael J. | COO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 27, 2024 | Aug 28, 2024 | Stauderman Kenneth A. | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 27, 2024 | Aug 28, 2024 | Roberts Eric W | CHIEF BUSINESS OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 27, 2024 | Aug 28, 2024 | Hebbar Sudarshan | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 27, 2024 | Aug 28, 2024 | Leheny A. Rachel | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 27, 2024 | Aug 27, 2024 | Leheny A. Rachel | CEO | Buy | 55.0 | +1,000 | 0.12% | ✗ | $4.2K |
| Aug 23, 2024 | Aug 26, 2024 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 68.8 | +5,000 | 0.55% | ✗ | $17.9K |
| Aug 23, 2024 | Aug 26, 2024 | WILSON ROBERT N | Director | Buy | 95.0 | +54,000 | 17.41% | ✗ | $200.8K |
| Aug 21, 2024 | Aug 22, 2024 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 68.8 | +5,000 | 0.55% | ✗ | $20.2K |
| Jun 28, 2024 | Jul 2, 2024 | WILSON ROBERT N | Director | Buy | 95.0 | +51,278 | 19.80% | ✗ | $180.5K |
| Jun 27, 2024 | Jul 1, 2024 | WILSON ROBERT N | Director | Buy | 83.8 | +8,443 | 3.37% | ✗ | $27.3K |
| Jun 27, 2024 | Jun 28, 2024 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 68.8 | +5,000 | 0.55% | ✗ | $16.1K |
| May 17, 2024 | May 20, 2024 | Geffken Daniel E. | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 28, 2024 | Apr 22, 2024 | Guerard Frederic | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 28, 2024 | Apr 22, 2024 | BJERKHOLT ERIC | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 28, 2024 | Apr 22, 2024 | Shaw Allan | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 28, 2024 | Apr 22, 2024 | MIDDLETON FRED A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 28, 2024 | Apr 22, 2024 | WILSON ROBERT N | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 28, 2024 | Apr 22, 2024 | Dunn Michael J. | COO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 28, 2024 | Apr 22, 2024 | Stauderman Kenneth A. | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 28, 2024 | Apr 22, 2024 | Roberts Eric W | CHIEF BUSINESS OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 28, 2024 | Apr 22, 2024 | Hebbar Sudarshan | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 28, 2024 | Apr 22, 2024 | Leheny A. Rachel | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2024 | Apr 2, 2024 | Roberts Eric W | CHIEF BUSINESS OFFICER | Buy | 61.3 | +4,000 | 0.44% | ✗ | $15.6K |
| Feb 5, 2024 | Feb 6, 2024 | Roberts Eric W | CHIEF BUSINESS OFFICER | Neutral | 90.0 | +91,086 | 11.23% | ✗ | - |
| Jan 23, 2024 | Jan 25, 2024 | MIDDLETON FRED A | Director | Buy | 100.0 | +679,384 | 41.34% | ✗ | $2.5M |
| Jan 23, 2024 | Jan 25, 2024 | Sanderling Venture Partners VI LP | 10% Owner | Buy | 100.0 | +679,384 | 41.84% | ✗ | $2.5M |
| Jan 23, 2024 | Jan 25, 2024 | Leheny A. Rachel | CEO | Neutral | 90.0 | +91,086 | 12.00% | ✗ | - |
| Jan 23, 2024 | Jan 25, 2024 | WILSON ROBERT N | Director | Neutral | 90.0 | +68,314 | 37.50% | ✗ | - |
| Dec 11, 2023 | Dec 13, 2023 | WILSON ROBERT N | Director | Buy | 60.0 | +506 | 0.28% | ✗ | $1.7K |
| Nov 7, 2023 | Nov 8, 2023 | Leheny A. Rachel | CEO | Buy | 60.0 | +2,000 | 0.26% | ✗ | $6.7K |
| Nov 6, 2023 | Nov 8, 2023 | Roberts Eric W | Chief Business Officer | Buy | 60.0 | +2,400 | 0.30% | ✗ | $7.5K |
| Nov 3, 2023 | Nov 7, 2023 | Roberts Eric W | Chief Business Officer | Buy | 78.8 | +14,949 | 1.88% | ✗ | $42.1K |
| Nov 6, 2023 | Nov 7, 2023 | Leheny A. Rachel | CEO | Buy | 60.0 | +2,440 | 0.32% | ✗ | $7.6K |
| Nov 3, 2023 | Nov 7, 2023 | Hebbar Sudarshan | Chief Medical Officer | Buy | 95.0 | +36,000 | 360.00% | ✗ | $98.6K |
| Nov 3, 2023 | Nov 6, 2023 | Roberts Eric W | Chief Business Officer | Buy | 78.8 | +9,060 | 1.15% | ✗ | $24.8K |
| Nov 3, 2023 | Nov 6, 2023 | Leheny A. Rachel | CEO | Buy | 68.8 | +5,000 | 0.67% | ✗ | $14.3K |
| Mar 20, 2023 | Oct 10, 2023 | Sanderling Venture Partners VI LP | 10% Owner | Neutral | 90.0 | +1,640,044 | 100.00% | ✗ | - |
| Oct 10, 2023 | Sanderling Venture Partners VI LP | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 29, 2023 | Sep 5, 2023 | Roberts Eric W | Chief Business Officer | Buy | 82.5 | +223 | 4.46% | ✗ | $673.5 |
| Aug 25, 2023 | Aug 29, 2023 | Roberts Eric W | Chief Business Officer | Buy | 55.0 | +736 | 0.09% | ✗ | $2.3K |
| Aug 21, 2023 | Aug 23, 2023 | Roberts Eric W | Chief Business Officer | Buy | 60.0 | +2,464 | 0.32% | ✗ | $8K |